Skip to main content

Advertisement

Table 3 Sensitivity analysis for incidence rates and risk of ischemic stroke associated with use of low-dose aspirin among patients with diabetes who completed more than 1 year follow-up periods after index date

From: Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study

  Aspirin non-user Low-dose aspirin user   
  Event (N) Person-years Crude incidence rate (/1,000 person-years) Event (N) Person-years Crude incidence rate (/1,000 person-years) Crude Hazard Ratio (95% CI) Adjusted Hazard Ratio * (95% CI)
Whole matched cohort 84 48,553 1.7 139 44,527 3.1 1.85 (1.41-2.44) 1.97 (1.51-2.62)
Gender Male 42 27,476 1.5 78 25,182 3.1 3.01 (2.12-4.28) 3.25 (2.28-4.63)
  Female 42 21,077 2.0 61 19,345 3.2 1.65 (1.65-2.45) 1.72 (1.16-2.57)
Age 40-69 48 39,633 1.2 85 37,019 2.3 1.98 (1.98-2.62) 2.12 (1.48-3.03)
  70-99 36 8,921 4.0 54 7,508 7.2 1.79 (1.79-2.74) 1.89 (1.23-2.91)
Type of diabetes Type 1 only 8 3,064 2.6 8 2,282 3.5 1.32 (0.50-3.52) 1.38 (0.50-3.77)
  Type 2 and others 76 45,489 1.7 131 42,245 3.1 1.91 (1.44-2.54) 2.05 (1.54-2.74)
Diabetes with essential hypertension Yes 48 24,669 1.9 82 21,272 3.9 2.03 (1.42-2.91) 2.14 (1.50-3.07)
No 36 23,885 1.5 57 23,225 2.5 1.67 (1.09-2.54) 1.78 (1.16-2.73)
Diabetes with dyslipidemia Yes 24 13,444 1.8 27 11,240 2.4 1.34 (0.78-2.34) 1.60 (0.92-2.82)
No 60 35,109 1.7 112 33,287 3.4 2.04 (1.49-2.80) 2.13 (1.55-2.93)
  1. CI: confidence interval.
  2. *Adjusted Hazard Ratio calculated using Cox proportional hazard model adjusting for insurance type, anti-diabetic medications at baseline, use of statins, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers and thiazide diuretics during follow-up.